9 diciembre 2014
New research shows that a combination of doxil, carboplatin and bevacizumab is a well-tolerated treatment regimen in patients with metastatic triple-negative breast cancer who received no prior treatment for their metastatic disease. The work also included genomic profiling to measure molecular correlates of response.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/Q5hL_Dhod60/141209091846.htm
